Evolution of the contract development and manufacturing business from CMO to CDMO
First written in FY2020. 1 of 3 entries say "Restated". Latest entry: FY2021.
2 other companies' latest entry also says "Advanced".
- FY2021AdvancedAnnual report
「We will evolve our existing CMO business and promote a CDMO business that provides one-stop development and manufacturing of biotechnology products by leveraging our proprietary development capabilities, thereby establishing a competitive advantage.」
The evolution from a CMO to a CDMO is being made concrete through development and manufacturing sites organized by specialty: クオリテックファーマ㈱, 日本点眼薬研究所 and the Kyoto Research Center. - FY2021-Q2RestatedAnnual report
「In addition to Nihon Eye Research Laboratories Co., Ltd., the subsidiaries engaged in contract pharmaceutical development and manufacturing also performed well.」
The performance of related subsidiaries in the contract development and manufacturing business has been reported as strong, reconfirming the development of that business. - FY2020First statedAnnual report
「We will evolve our existing contract manufacturing organisation (CMO) business and promote a contract development and manufacturing organisation (CDMO) business that provides one-stop development and manufacturing by leveraging our proprietary development capabilities, thereby establishing a competitive advantage.」
The Company has newly established an initiative to evolve its existing contract manufacturing organization (CMO) business into a CDMO offering one-stop services from development through manufacturing.